 Daxor Corporation NYSE American: DXR Daxor or the Company, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has closed its previously announced registered direct offering priced at-the-market of 140,352 shares of its common stock at a price of 14.25 per share, for aggregate gross proceeds of approximately 2.0 million. The Company intends to use the net proceeds for working capital and other general corporate purposes. Maxim Group LLC served as a financial advisor to Daxor in regards to the transaction. 